Currently in development, there is a multi-cancer screening tool that is showing promise of being able to simultaneously screen multiple cancer types through a blood test. The Galleri® test detects a signal shared by more than 50 cancer types. When a cancer signal is detected, the test compares the methylation pattern to the Cancer Signal Origin patterns of 21 possible predictions. In studies, it showed an 88% accuracy rate in which the Cancer Signal Origin was consistent with the type of cancer confirmed. By having the cancer origin predicted ahead, providers were able to select the appropriate diagnostic testing to perform next.30
In current studies, it has a 99.5% specificity rate with a low false positive rate of 0.5%. The overall sensitivity for cancer detection is 51.5% for all cancers and stages.30
